TY - JOUR
T1 - Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-Naïve patients prescribed efavirenz compared to atazanavir/ritonavir
AU - Gotti, Daria
AU - Cesana, Bruno Mario
AU - Albini, Laura
AU - Calabresi, Alessandra
AU - Izzo, Ilaria
AU - Focà, Emanuele
AU - Motta, Davide
AU - Bellagamba, Rita
AU - Fezza, Rita
AU - Narciso, Pasquale
AU - Sidhinolfi, Laura
AU - Maggi, Paolo
AU - Brianese, Nigritella
AU - Quiros-Roldan, Eugenia
AU - Guaraldi, Giovanni
AU - Torti, Carol
PY - 2012/1/1
Y1 - 2012/1/1
N2 - Background: Cardiovascular risk in HIV-infected patients is related, at least in part, to serum lipid alterations before and after HAART. Lipoprotein-particle subclasses may also have an effect, but comparative data after standard HAART regimens are limited.Methods: This was a substudy of a trial in 91 antiretroviral-naïve patients randomized to tenofovir + emtricitabine + atazanavir/ritonavir (ATV/r) or efavirenz (EFV). Over-time trends from baseline to week 48 in total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), HDL particles (HDLp), and TC:HDL-C and TG:HDL-C ratios were analyzed by analysis of covariance (ANCOVA). Furthermore, confidence intervals for differences between the 2 groups at week 48 were calculated. Indications for lipid-lowering interventions and low HDL-C were also studied.Results: ANCOVA showed that, with respect to patients receiving ATV/r, those prescribed efavirenz (EFV) had greater increases reported as mean differences in lipid values at week 48: 14 mg/dL (95% CI, 0.2 to 27) for TC, 14 mg/dL (95% CI, 4 to 25) for LDL-C, 5 mg/dL (95% CI, 2 to 9) for HDL-C, and 2.2 mg/dL (95% CI, 0.4 to 4) for large HDLp. Proportions of subjects with indications for lipid-lowering interventions and with HDL-C
AB - Background: Cardiovascular risk in HIV-infected patients is related, at least in part, to serum lipid alterations before and after HAART. Lipoprotein-particle subclasses may also have an effect, but comparative data after standard HAART regimens are limited.Methods: This was a substudy of a trial in 91 antiretroviral-naïve patients randomized to tenofovir + emtricitabine + atazanavir/ritonavir (ATV/r) or efavirenz (EFV). Over-time trends from baseline to week 48 in total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), HDL particles (HDLp), and TC:HDL-C and TG:HDL-C ratios were analyzed by analysis of covariance (ANCOVA). Furthermore, confidence intervals for differences between the 2 groups at week 48 were calculated. Indications for lipid-lowering interventions and low HDL-C were also studied.Results: ANCOVA showed that, with respect to patients receiving ATV/r, those prescribed efavirenz (EFV) had greater increases reported as mean differences in lipid values at week 48: 14 mg/dL (95% CI, 0.2 to 27) for TC, 14 mg/dL (95% CI, 4 to 25) for LDL-C, 5 mg/dL (95% CI, 2 to 9) for HDL-C, and 2.2 mg/dL (95% CI, 0.4 to 4) for large HDLp. Proportions of subjects with indications for lipid-lowering interventions and with HDL-C
KW - antiretroviral therapy
KW - cardiovascular risk
KW - human immunodeficiency virus
KW - lipids
KW - lipoproteins
UR - http://www.scopus.com/inward/record.url?scp=84868695746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868695746&partnerID=8YFLogxK
U2 - 10.1310/hct1305-245
DO - 10.1310/hct1305-245
M3 - Article
C2 - 23134625
AN - SCOPUS:84868695746
SN - 1528-4336
VL - 13
SP - 245
EP - 255
JO - HIV Clinical Trials
JF - HIV Clinical Trials
IS - 5
ER -